Document is current
Any future updates will be listed below
-
Authors
Kool, Heleen M.
Bürgisser, Petra E.
Edel, Gabriela G.
Boerema-de Munck, Anne
Buscop-van Kempen, Marjon
Liakopoulos, Panagiotis
Kolovos, Petros
van Ijcken, Wilfred F. J.
Rottier, Robbert J. https://orcid.org/0000-0002-9291-4971
-
Funding
Funding for this research was provided by:
Stichting Vrienden van het Sophia (678)
Stichting Vrienden van het Sophia (S15-11)
Aard- en Levenswetenschappen, Nederlandse Organisatie voor Wetenschappelijk Onderzoek (019.162LW.011)
H2020 Marie Skłodowska-Curie Actions (H2020-MSCA-IF-2017)
- License Information
-
More Information
Article History
Received: 12 February 2026
Accepted: 20 June 2026
First Online: 20 July 2026
Declarations
Ethics approval: Animal experimentation: All animal experimental protocols were approved by a national committee (“Centrale Commissie Dierproeven”; numbers AVD101002017871 and AVD10100202216366) and by the animal welfare committee of the veterinary authorities (protocol numbers 17-871-01 and 17-871-02) of the Erasmus Medical Center. Human primary ECFC cells: The human study was reviewed and approved by the Daily Board of the Medical Ethics Committee (METC) of Erasmus MC Rotterdam, The Netherlands (MEC-2017-302).
Consent to participate: Not applicable.
Consent to publish: Not applicable.
Competing interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as potential conflicts of interest.
